AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
10.9 C
New York
Saturday, October 17, 2026

Tag: therapy

newssourceFORcompanycontentinformation1releasesmarket

Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2025 Outlook

ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended June 28, 2025.

IBA Notice of Half Year 2025 Results and Conference Call

HY25 results webcast to take place on 
Thursday, 28 August 2025 at 3pm CEST

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Dreame Technology Unleashes Eleven Smart Home Breakthroughs, Ushering in a New Era of Intelligent Living in the U.S.

The new lineup spans AI-powered cleaning solutions and next-gen personal care tools—setting a bold course for Dreame's North American expansion. NEW YORK, Aug. 6, 2025...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

ONWARD Medical gibt Ernennung von Lucas Buchanan als Vorstandsmitglied bekannt

EINDHOVEN, Niederlande, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD und US OTCQX: ONWRY), das führende Neurotechnologieunternehmen, das Pionierarbeit bei Therapien zur Wiederherstellung der Bewegungsfähigkeit, Funktion und Unabhängigkeit von Menschen mit Rückenmarksverletzungen (Spinal cord injury, SCI) und anderen Bewegungseinschränkungen leistet, gibt heute die Ernennung von Lucas Buchanan als nicht geschäftsführendes Mitglied seines Vorstands bekannt.

Immix Biopharma Announces Other Serious Diseases Strategy

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –

Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting

The Biomarkers Market is anticipated to expand at a rapid pace due to the increasing demand for personalized medicine, rising prevalence of chronic and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers